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Introduction
In analyzing randomized clinical trials, trialists typically focus on
treatment effects relative to a comparator and consider speciﬁc
outcomes individually. Nevertheless, recognizing that, in prac-
tice, there is systematic variation in the beneﬁt that patients
derive from medical treatments, the question becomes how to
incorporate multidimensional outcomes and multifactorial het-
erogeneity in the context of comparative effectiveness to capture
the incremental beneﬁt across all outcomes. The role of subgroup
analysis in the context of clinical trials, cost-effectiveness analy-
sis, and comparative effectiveness are discussed.
Subgroup Analysis in Clinical Trials
In general, the clinical trial paradigm assesses individual end
points separately and discretely, and focuses on relative treatment
effects relating to subgroups. Clinical trials are usually powered
to test one or two primary endpoints (e.g., an efﬁcacy end point
and a safety end point). Subgroup analysis is used to determine
whether statistically signiﬁcant interactions exist between char-
acteristics of the patients and the relevant measures of relative
treatment effects.
An example of a classic clear-cut subgroup analysis is seen in
the clinical trial comparing two antithrombotic treatments
(enoxaparin and fondaparinux) for patients with non-ST eleva-
tion acute coronary syndrome: OASIS-5 Investigators et al. [1].
In this study, the investigators focused on the hazard ratio as an
indicator of the relative treatment effect with respect to the
primary measure of efﬁcacy (a composite of death, myocardial
infarction (MI), and refractory ischemic pain at 9 days) or safety
(major bleeding at 9 days). Subgroup analysis focused on the
interaction of safety and efﬁcacy end points with patients’ base-
line age, gender, creatinine levels relative to median, use of
heparin, and need for revascularization in the previous 9 days.
The subgroup analysis showed no statistically signiﬁcant inter-
action in terms of efﬁcacy and, at 9 days, there was no overall
difference between the two groups. With respect to safety, a
marked overall beneﬁt of the new agent (fondaparinux) was
demonstrated in terms of reducing major bleeding episodes at 9
days, with a consistent direction of effect for all of the subgroups
that were considered.
In practice, moving from clinical trial data to a decision-
making context is often complicated by inconsistency in the
direction of the treatment effect across subgroups. Speciﬁcally,
the difﬁculty comes when there are trade-offs; for example, a gain
in efﬁcacy, but some loss in safety, or vice versa. In this context,
some basis for evaluating the trade-off is required—for example,
to assess whether the gains in efﬁcacy are worth the loss in safety.
This requires a movement from the focus on relative treatment
effects to a consideration of the beneﬁts and disbeneﬁts of treat-
ment on an absolute scale (e.g., expressed in terms of mortality
risk, bleeding adverse events). Furthermore, to assess the net-
beneﬁt of one treatment versus another (i.e., whether beneﬁts are
greater than disbeneﬁts), it is necessary to place positive and
negative effects on to a single scale. There are various approaches
to this form of “net-beneﬁt analysis” or “risk-beneﬁt analysis”
[2], including the use of patients’ or public values to generate a
preference-weighted overall measure of (net) beneﬁt.
Subgroup Analysis of Cost-Effectiveness Data
In cost-effectiveness analysis (CEA), the central question to
address is whether the additional beneﬁts generated by a given
intervention, compared with an alternative, are worth any addi-
tional cost [3]. Relative treatment effects are therefore insufﬁcient
for CEA because there is a need to know how more beneﬁcial the
intervention is and not just that it is more beneﬁcial. Further-
more, the need to make trade-offs between different outcomes is
commonplace. Preferences are frequently used to provide a
weighted measure of beneﬁt on a single scale. Outside the ﬁeld of
health, these preferences are often expressed in terms of individu-
als’ willingness to pay. Within health, the most widely used form
of preference-weighted beneﬁt is the quality-adjusted life-year
(QALY). Furthermore, subgroup analysis is increasingly used
with CEA to establish in which types of patients an intervention
provides the greatest value for money.
Taking the data from the study of antithrombotic treatments
described previously, Sculpher et al. undertook a cost-
effectiveness analysis of the interventions [4]. To assess sub-
groups, the analysis started by determining the relative variation
in risk of the composite efﬁcacy and safety events according to a
range of patient characteristics including age, sex, and history of
previous coronary events (as well as treatment allocation) [4].
Table 1 shows the results of this analysis for two end points at
180 days—death and nonfatal MI. These data clearly show the
systematic variation in risk depending on the type of patient. For
example, the risk of death by 180 days after an episode of acute
coronary syndrome is more likely in men, older patients, and
diabetics.
These estimates of differential event risk by patient charac-
teristics were used to undertake a subgroup analysis in terms of
the cost-effectiveness of the two antithrombotic treatments
(enoxaparin and fondaparinux). This showed how cost-
effectiveness varies according to underlying (or baseline) risk of
the composite outcome of death, nonfatal MI and nonfatal
stroke. This assumed that treatment effectiveness is common
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across all subgroups (as shown in the clinical analysis of the
OASIS-5 trial). As illustrated in Table 2, the analysis showed
that, at a cost-effectiveness threshold of $50,000 per QALY for
patients who have the average characteristics seen in the OASIS-5
trial, treatment with the new agent (fondaparinux) is cost effec-
tive, with similar results obtained for patients at low or high
baseline risk of the composite outcome. Although fonda-
parinux’s cost-effectiveness was consistent across subgroups, the
application of a common relative treatment effect to a varying
baseline risk resulted in subgroup differences in the absolute
beneﬁt of treatment. As shown in Table 2, the absolute lifetime
QALYs for patients at low baseline risk of events is much higher
than for the average patient for both treatment groups, but the
additional beneﬁt of fondaparinux is slightly lower than for the
average patient. Patients who are at high baseline risk have
relatively low lifetime QALY estimates, but the additional beneﬁt
of fondaparinux is greater.
Subgroup Analysis with Comparative Effectiveness
If we are explicit about the need to focus on absolute beneﬁt to
inform clinical decision-making, and about the sources of het-
erogeneity that might cause the absolute beneﬁt to vary between
patients, then we can apply essentially the same approach used
in determining cost-effectiveness to determine comparative
effectiveness, simply by leaving out the cost. To illustrate this,
Table 3 shows the expected QALYs from the cost-effectiveness
subgroup analysis of enoxaparin and fondaparinux described
previously and represents a measure of net clinical beneﬁt on
the absolute QALY scale, and this relates to different levels of
baseline risk of clinical events. It is also possible to calculate the
probability of a net gain in health compared to a loss in health
if a patient takes fondapurinax compared with enoxaparin
(shown in Table 3); this reﬂects the uncertainty in the underly-
ing evidence base.
In this example, there is full consistency in terms of the
impact of the new drug on patient health at different risk levels.
Nevertheless, there are many clinical examples where there is a
signiﬁcant trade-off between efﬁcacy end points and safety end
points in which consistency across subgroups may not be
observed. In these cases, a measure of absolute beneﬁt may be
most informative. For example, Minelli et al. considered the net
clinical beneﬁt of hormone replacement therapy (HRT) in terms
of QALYs for women at different baseline risks of breast cancer
Table 1 Modeling of underlying risk of events at 180 days in patients with non-ST-elevation acute coronary syndrome in the OASIS-5 study
Explanatory baseline variables
Death Nonfatal MI
HR 95% CI HR 95% CI
Use of fondaparinux 0.892 0.797–0.999 0.945 0.833–1.073
Age at study entry (y) 1.060 1.053–1.067 1.022 1.015–1.028
Male 1.103 0.976–1.247 1.263 1.094–1.458
History of heart failure 1.876 1.652–2.130 1.025 0.856–1.227
History of diabetes 1.436 1.274–1.618 1.239 1.077–1.428
History of hypertension 0.979 0.857–1.119 1.038 0.898–1.200
ST depression at study entry 1.785 1.581–2.015 1.232 1.083–1.401
Serum creatinine 2 1.054 0.870–1.277 0.857 0.708–1.037
Serum creatinine 3 1.286 1.070–1.546 1.044 0.868–1.256
Serum creatinine 4 1.865 1.566–2.220 1.102 0.911–1.333
Constant (on the log scale) -10.32 -10.85 to -9.79 -6.972 -7.48 to -6.47
Ancillary parameter 0.505 0.478–0.534 0.429 0.403–0.456
Adapted from Sculpher et al. [4].
Table 2 Example of a subgroup analysis of cost-effectiveness
Enoxaparin Fondaparinux Fondaparinux vs. Enoxaparin
Patient with average characteristics
Expected cost $79,905 $79,717
Expected quality-adjusted life-years 7.06 7.10
Probability most cost-effective at a threshold of $50,000 per QALY 0.7% 99.3%
Probability of cost saving 17.6% 82.4%
Difference in costs per 1,000 patients -$188,000
Difference in QALYs per 1,000 patients 40
Incremental cost-effectiveness Fondaparinux dominates
Patient at low risk of composite event over 180 d (2.5th percentile)
Expected cost $115,163 $114,998
Expected quality-adjusted life-years 12.95 12.98
Probability most cost-effective at a threshold of $50,000 per QALY 0.1% 99.9%
Probability of cost saving 14.0% 86.0%
Difference in costs per 1,000 patients -$165,000
Difference in QALYs per 1,000 patients 30
Incremental cost-effectiveness Fondaparinux dominates
Patient at high risk of composite event over 180 d (97.5th percentile)
Expected cost $57,968 $57,643
Expected quality-adjusted life-years 3.38 3.48
Probability most cost-effective at a threshold of $50,000 per QALY 0.8% 99.2%
Probability of cost saving 17.5% 82.5%
Difference in costs per 1,000 patients -$325,000
Difference in QALYs per 1,000 patients 100
Incremental cost-effectiveness Fondaparinux dominates
Adapted from Sculpher et al. [4].
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[5]. They assessed how the expected (or mean) net clinical beneﬁt
of HRT changed as the baseline risk of breast cancer increased.
With the use of a preference-weighted scale that incorporates
risks and beneﬁts, we can also reﬂect uncertainty in the evidence
base. Minelli et al. for example, used Bayesian methods to
present the 95% credibility interval around net clinical beneﬁt
for the average patient, as well as the probability of net harm for
a given baseline risk of breast cancer [5].
The Impact of Patient Preferences
In addition to systematic variation in underlying risks and treat-
ment effect, patient preferences can be a major source of hetero-
geneity in health outcomes. This is because individuals often have
different attitudes to the trade-offs between efﬁcacy end points
and side-effect end points that affect the success of treatment.
These may include, for example, considerations of pain, physical
function, mental well-being, social function, and life expectancy.
As with underlying risk, the beneﬁt that individual patients
derive from a treatment varies with their preferences. A
preference-weighted measure of beneﬁt, such as a QALY, can
reﬂect this heterogeneity in preferences.
Figure 1 illustrates the idea of a distribution of health for
patients deriving beneﬁt from minimally invasive surgical tech-
niques compared with open surgical techniques. On the left of
the distribution are those patients who derive less beneﬁt from
minimal access surgery and on the right are those patients who
derive more beneﬁt. In terms of preferences, those on the left of
the distribution may be, for example, the patients who would
prefer a “once and for all” solution, on the basis that minimal
access surgery may require the need to return for further treat-
ment, or they may be more worried about the nonfatal compli-
cations of minimally invasive surgery than they are about the
higher mortality risk associated with open surgery. In contrast,
patients to the right of the distribution expect to gain more in
terms of beneﬁt, perhaps because they prefer the shorter conva-
lescence associated with minimal access surgery, or they may be
less worried about the failure risk of this procedure and more
worried about the higher mortality risk associated with open
surgery.
A speciﬁc example of an analysis of the effects of patient
preferences on expected QALYs is provided in the comparison of
minimal access surgery, transcervical resection, versus an open
surgical technique, abdominal hysterectomy, in the treatment of
menorrhagia [6]. Eliciting women’s preferences for aspects of
these two treatments revealed considerable variation in how
those preferences inﬂuenced the QALYs gained from each type of
treatment. On average, a higher number of expected QALYs
were associated with open surgery (the traditional and more
invasive procedure). Nevertheless, the distribution of QALYs for
these two procedures indicated that not all women would beneﬁt
more from open surgery. In fact, it appeared that many women
would get more beneﬁt from transcervical resection, not because
of any underlying clinical difference between the women or any
treatment modifying effect, but because their preferences are
different. This example serves to emphasize the need to reﬂect the
heterogeneity in preferences when making clinical decisions.
Closing Remarks
Two fundamental assumptions that are routinely applied in cost-
effectiveness analysis are transferable to the quantiﬁcation of
comparative effectiveness:
1. The need to express health beneﬁt on a single scale in light
of the positive and negative dimensions of effects—as the
most widely used and understood weighted measure of
beneﬁt; the QALY is perhaps the most obvious candidate
for such a scale because it applies to comparative effective-
ness. Nevertheless, other methods exist such as discrete
choice methods [7].
2. Heterogeneity of clinical trial data is not only associated
with the treatment effect on selected outcomes, it encom-
passes absolute health beneﬁt—comparative effectiveness
analysis needs to accommodate the potential effects of
variation in baseline risk in different types of patients, as
well as patient preferences on absolute risk reduction.
Table 3 Possible comparative effectiveness subgroup analysis
Enoxaparin Fondaparinux
Patient with average characteristics
Expected quality-adjusted life-years 7.06 7.10
Probability of net clinical beneﬁt 0.01 0.99
Patient at low risk of composite event over
180 days (2.5th percentile)
Expected quality-adjusted life-years 12.95 12.98
Probability of net clinical beneﬁt 0.01 0.99
Patient at high risk of composite event over
180 days (97.5th percentile)
Expected quality-adjusted life-years 3.38 3.48
Probability of net clinical beneﬁt 0.01 0.99
Net QALYs gained from minimal access surgery
Prefer ‘once and for all’ solution
Unworried by higher mortality risk
Worried by non-fatal complications
Prefer shorter convalescence
Worried by higher mortality risk
Unworried by failure risk
Zero net QALYs
Figure 1 Example of a distribution of net health
beneﬁt reﬂecting heterogeneity in preferences.
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In an environment with or without resource constraints,
absolute measures of net beneﬁt are the key to clinical decision-
making, whether for an individual patient or a group of patients.
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